Augmentin®

DRUG4 trials

Sponsors

Teva Pharmaceuticals USA, Pharmtechnology LLC

Conditions

BioequivalenceHealthy

Phase 1

Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditions

CompletedNCT00835705

Teva Pharmaceuticals USAHealthy

Start: 2003-09-30End: 2003-09-30Updated: 2024-08-20

Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions

CompletedNCT00836901

Teva Pharmaceuticals USAHealthy

Start: 2003-09-30End: 2003-09-30Updated: 2024-08-21

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

CompletedNCT03616301

Pharmtechnology LLCBioequivalence

Start: 2018-07-28End: 2018-08-13Updated: 2018-10-15

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

CompletedNCT03702894

Pharmtechnology LLCBioequivalence

Start: 2018-09-21End: 2018-10-08Updated: 2019-05-14